drugset / Trial / NCT04989855
Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, one arm phase II study aimed to observe the efficacy and safety of tislelizumab combined with fruquintinib in treatment of patients with pMMR / MSS locally advanced rectal cancer with high immune score.
Timeline
- Start
- 2021-08
- Primary completion
- 2022-08
- Completion
- 2024-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 5 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.